Pfizer Inc (PFE) 28.94 $PFE
Most active New York Stock Exchange-traded stocks
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Pfizer Submits Palbociclib Marketing Application to the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 3:20PM CDT
Pfizer Inc. (PFE) announced that it has submitted the marketing application for its oncology candidate, palbociclib, to the FDA.
Midday Glance: Pharmaceuticals companies
AP - Tue Aug 19, 3:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer files NDA of Palbociclib with US FDA for breast cancer
M2 - Tue Aug 19, 10:34AM CDT
Healthcare company Pfizer (NYSE
FE) revealed on Monday the completion of the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for palbociclib for the treatment of women with advanced or metastatic ER+, HER2- breast cancer.
3 Reasons Pfizer Inc.'s Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 19, 10:01AM CDT
Pfizer , arguably the preeminent pharmaceutical company in the world, continues to pump out billions in free cash flow annually, deliver delectable gross margins, and pay out an annual dividend that puts the S&P 500 average yield of 2% to...
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana
PR Newswire - Tue Aug 19, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Humana Inc. (NYSE: HUM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5808-100free.
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
Pfizer (PFE) Breaks Through Resistance at $28.89
Comtex SmarTrend(R) - Mon Aug 18, 11:02AM CDT
Shares of Pfizer (NYSE FE) have bullishly opened above the pivot of $28.65 today and have reached the first resistance level of $28.89. Investors may be interested in a cross of the next upside pivot targets of $29.14 and $29.63.
Early Glance: Pharmaceuticals companies
AP - Mon Aug 18, 9:29AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Global Antifungal Therapeutics Market 2014 Trends and Opportunities New Study Now Available at MarketReportsOnline.com
PRWeb - Mon Aug 18, 8:31AM CDT
The report titled "Global Antifungal Therapeutics Market: Trends and Opportunities (2014-2019)" provides an in-depth analysis of global antifungal therapeutics market with focus on antifungal drug classes - Polyenes, Azoles, Echinocandins and Allylamines. It provides broad coverage of these classes with detailed analysis of drugs and indications in respective classes. It also assesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2014-19). Further, key players of the industry such as Merck & Co., Inc., Pfizer Inc., Astellas Pharma Inc. and Noble Corporation SCYNEXIS, Inc. are also profiled in the report.
Premier Biotechnology & Anti-CTLA4
ACCESSWIRE - Mon Aug 18, 7:02AM CDT
Whitefish, MT / August 18, 2014 / Many forms of cancer are characterized by a lack of cellular apoptosis (e.g. cell death) and down-regulation of the immune system. In the case of the latter, cytotoxic T lymphocytes ("CTLs"
are largely responsible for recognizing and killing cancer cells, but there are some inhibitory mechanisms that interrupt the destruction and prevents cancer cells from being targeted and destroyed.
Pfizer Announces Submission of Palbociclib New Drug Application to the FDA
Business Wire - Mon Aug 18, 7:00AM CDT
Pfizer Inc. today announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients.
Stock Market News for August 15, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 9:10AM CDT
Markets ended in the green as Russian president’s comments eased concerns related to geopolitical tensions
Pfizer reports US FDA's acceptance of Biologics License Application and Priority Review designation for meningococcal B vaccine candidate
M2 - Fri Aug 15, 7:40AM CDT
Science company Pfizer (NYSE FE) said on Thursday that it has filed its Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for review for its vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B.
Most active New York Stock Exchange-traded stocks
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Pfizer Submits Palbociclib Marketing Application to the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 3:20PM CDT
Pfizer Inc. (PFE) announced that it has submitted the marketing application for its oncology candidate, palbociclib, to the FDA.
Midday Glance: Pharmaceuticals companies
AP - Tue Aug 19, 3:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer files NDA of Palbociclib with US FDA for breast cancer
M2 - Tue Aug 19, 10:34AM CDT
Healthcare company Pfizer (NYSE
FE) revealed on Monday the completion of the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for palbociclib for the treatment of women with advanced or metastatic ER+, HER2- breast cancer. 3 Reasons Pfizer Inc.'s Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 19, 10:01AM CDT
Pfizer , arguably the preeminent pharmaceutical company in the world, continues to pump out billions in free cash flow annually, deliver delectable gross margins, and pay out an annual dividend that puts the S&P 500 average yield of 2% to...
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana
PR Newswire - Tue Aug 19, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Humana Inc. (NYSE: HUM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5808-100free.
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
Pfizer (PFE) Breaks Through Resistance at $28.89
Comtex SmarTrend(R) - Mon Aug 18, 11:02AM CDT
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $28.65 today and have reached the first resistance level of $28.89. Investors may be interested in a cross of the next upside pivot targets of $29.14 and $29.63. Early Glance: Pharmaceuticals companies
AP - Mon Aug 18, 9:29AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Global Antifungal Therapeutics Market 2014 Trends and Opportunities New Study Now Available at MarketReportsOnline.com
PRWeb - Mon Aug 18, 8:31AM CDT
The report titled "Global Antifungal Therapeutics Market: Trends and Opportunities (2014-2019)" provides an in-depth analysis of global antifungal therapeutics market with focus on antifungal drug classes - Polyenes, Azoles, Echinocandins and Allylamines. It provides broad coverage of these classes with detailed analysis of drugs and indications in respective classes. It also assesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2014-19). Further, key players of the industry such as Merck & Co., Inc., Pfizer Inc., Astellas Pharma Inc. and Noble Corporation SCYNEXIS, Inc. are also profiled in the report.
Premier Biotechnology & Anti-CTLA4
ACCESSWIRE - Mon Aug 18, 7:02AM CDT
Whitefish, MT / August 18, 2014 / Many forms of cancer are characterized by a lack of cellular apoptosis (e.g. cell death) and down-regulation of the immune system. In the case of the latter, cytotoxic T lymphocytes ("CTLs"
are largely responsible for recognizing and killing cancer cells, but there are some inhibitory mechanisms that interrupt the destruction and prevents cancer cells from being targeted and destroyed. Pfizer Announces Submission of Palbociclib New Drug Application to the FDA
Business Wire - Mon Aug 18, 7:00AM CDT
Pfizer Inc. today announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients.
Stock Market News for August 15, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 9:10AM CDT
Markets ended in the green as Russian president’s comments eased concerns related to geopolitical tensions
Pfizer reports US FDA's acceptance of Biologics License Application and Priority Review designation for meningococcal B vaccine candidate
M2 - Fri Aug 15, 7:40AM CDT
Science company Pfizer (NYSE
FE) said on Thursday that it has filed its Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for review for its vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B. 
